[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531282":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"chemoradiotherapy combined with immunotherapy",null,"Patients treated with chemoradiotherapy combined with immunotherapy",[13],"Drug: cisplatin-based chemoradiotherapy combined with immunotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","cisplatin-based chemoradiotherapy combined with immunotherapy","Chemotherapy:cisplatin-based chemotherapy\n\nGP\u002FTP\u002FPF\u002FTPF\n\nChoice of chemotherapy regimen is decided by patient's doctor in charge.\n\nRadiation: Intensity Modulated Radiation Therapy\n\nAll target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).\n\nImmunotherapy:PD-1 blocking antibody",[9],[21],{"name":22,"affiliation":23,"role":24},"Chong Zhao, M.D","Sun Yat-Sen University Cancer Center","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Jingjing Miao, M.D","CONTACT","86-13631355201","miaojingjing90@163.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Cancer Center, Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":40,"coordinates":41},"Point",[42,43],113.25,23.11667,{"lat":43,"lon":42},[46],{"name":22,"role":28,"phone":47,"phoneExt":10,"email":48},"02087342638","zhaochong@sysucc.org.cn",{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Zhao Chong","Professor","100531282","investigation-of-multi-omics-technique-to-predict-the-efficacy-of-chemoradiotherapy-combined-with-immunotherapy-for-rm-npc-100531282",false,"NCT06197776","Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r\u002Fm NPC","Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for Recurrent and\u002For Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Recurrent or metastatic nasopharyngeal carcinoma patients\n* All genders，range from 18～70 years old\n* ECOG score 0 \\~ 1\n* Inform consent form\n\nExclusion Criteria:\n\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts;\n* Mental disorder;\n* Pregnancy or lactation;\n* Severe complication, eg, uncontrolled hypertension.","ALL","18 Years","70 Years",{"count":63,"type":64},50,"ESTIMATED","OBSERVATIONAL","The observational clinical study will recruit 50 recurrent and\u002For metastatic nasopharyngeal carcinoma (r\u002FmNPC) patients, to investigate the prediction values of multi-omics technique for the efficacy of chemoradiotherapy combined with immunotherapy.",[68,69,70,71],"Multi-omics Technique","Nasopharyngeal Carcinoma","Recurrent and Metastatic Nasopharyngeal Carcinoma","Efficacy of Chemoradiotherapy and Immunotherapy","2026-05-06",{"date":74,"type":75},"2026-05-11","ACTUAL",{"date":77,"type":75},"2024-07-15",{"date":79,"type":64},"2028-12",{"name":5,"class":6},1]